SPRED2 and prostate adenocarcinoma: Previous studies demonstrated that Spred2 mRNA expression was decreased in hepatocellular carcinoma (HCC) [31] and prostatic adenocarcinoma [32], comparing with that in adjacent non-tumor tissue and benign gland, respectively.